Why the study?
Traditional CVD examination requires bulky hospital instruments that are time-consuming and inconvenient, highlighting the need for rapid biosensor screening and continuous monitoring.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Biosensor advances may enable point-of-care CVD screening; leaves open whether they improve outcomes in prospective studies.
Cardiovascular disease (CVD) causes significant mortality and remains the leading cause of death globally. Thus, to reduce mortality, early diagnosis by measurement of cardiac biomarkers and heartbeat signals presents fundamental importance. Traditional CVD examination requires bulky hospital instruments to conduct electrocardiography recording and immunoassay analysis, which are both time-consuming and inconvenient. Recently, development of biosensing technologies for rapid CVD marker screening attracted great attention. Thanks to the advancement in nanotechnology and bioelectronics, novel biosensor platforms are developed to achieve rapid detection, accurate quantification, and continuous monitoring throughout disease progression. A variety of sensing methodologies using chemical, electrochemical, optical, and electromechanical means are explored. This review first discusses the prevalence and common categories of CVD. Then, heartbeat signals and cardiac blood-based biomarkers that are widely employed in clinic, as well as their utilizations for disease prognosis, are summarized. Emerging CVD wearable and implantable biosensors and monitoring bioelectronics, allowing these cardiac markers to be continuously measured are introduced. Finally, comparisons of the pros and cons of these biosensing devices along with perspectives on future CVD biosensor research are presented.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: